Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 Infection
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV Infection in Subjects Who Are Positive for HPV16/18
This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All participants must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. Subjects who meet all inclusion criteria will report to the study site on Day 0 and be assigned to a specific dosage group. Following the completion of eligibility assessments and baseline safety evaluations, subjects will receive an injection of the HPV-targeting nucleic acid therapeutic on Day 0, Day 21 (±3 days), and Day 42 (±3 days).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study is an open-label, single-arm clinical trial designed to evaluate a therapeutic intervention for HPV infection in subjects who test positive for HPV16/18. The study aims to enroll 300 subjects. All subjects must be confirmed as HPV16/18-positive via HPV genotyping nucleic acid testing during the screening phase. The study is divided into two phases:
Phase 1: This phase includes two dosage groups-0.05 mg and 0.5 mg. Subjects will be assigned to one of these dosage groups according to pre-established allocation rules and will receive a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.
Phase 2: This phase consists of a 0.5 mg dosage group, with subjects receiving a dose on Day 0 (D0), Day 21 (D21), and Day 42 (D42). Subjects will undergo short-term follow-ups on Day 70 (D70) and Day 126 (D126), as well as long-term follow-ups approximately 6 months and 12 months after the third dose.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Mingli Li
- 電話番号:+86 13718410348
- メール:minglili@aeonvital.com
研究場所
-
-
Hebei
-
Qinhuangdao、Hebei、中国
- 募集
- Beidaihe Hospital of Qinhuangdao City
-
コンタクト:
- Yanqiu Zheng
- 電話番号:+86 185 3358 8529
- メール:18310917293@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants must be aged 18-64 years (inclusive); only female participants will be enrolled.
- Subjects will voluntarily join the study and sign an informed consent form.
- During the screening period, there shall be no clinically significant abnormalities in medical history, physical examination, vital signs, 12-lead electrocardiogram, or clinical laboratory test results; the investigator will determine that the subject is suitable for enrollment.
- During the screening period, the HPV16/18 genotyping nucleic acid test result must be positive, and the subject must meet one of the following criteria: (1) a positive HPV16/18 test record during the screening period, with no current evidence of intraepithelial lesions; (2) a diagnosis of high-grade intraepithelial lesions of the cervix, vagina, or vulva confirmed by histopathological examination, with the subject meeting the enrollment criteria and treatment plan after specialist assessment; (3) the subject has previously undergone surgery or other local treatment for a related intraepithelial lesion, and the HPV16/18 test remains positive during the screening period, with no residual lesions currently present, or histopathological examination confirms the presence of residual or recurrent low-grade or high-grade intraepithelial lesions. (HPV subtype test results obtained within 30 days prior to administration, as well as TCT results and pathological biopsy results obtained within 90 days prior to administration, are acceptable).
- Fertile subjects (defined as females who have not undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, and whose menopause has occurred for ≥12 months) must agree to use highly effective contraceptive measures with their partner during the study treatment period and for at least 12 months after the final dose, including oral contraceptives, intrauterine devices, barrier contraception combined with spermicidal agents, or partner sterilization.
- Female subjects during the screening period must have negative serum or urine pregnancy tests and must not be in the lactation period. Be willing to undergo pregnancy testing during the screening period, before each dose administration, and at the end of the study.
- Be willing and able to comply with and complete all study procedures.
Exclusion Criteria:
- Presence of any skin condition on the upper arm that may interfere with the assessment of the injection-site reaction (ISR), including but not limited to extensive tattoos, scars, rashes, infections, or wounds.
- Presence of severe poor venous condition that precludes blood sample collection as required by the protocol.
- Presence, during screening, of an acute infection of the genital or anal region requiring systemic anti-infective therapy (excluding HPV infection).
- Pregnancy or lactation; or a history of miscarriage within the 3 months preceding screening.
- Any medical condition judged by the investigator to increase the risk of biopsy-related bleeding.
- In addition to the study indication, any clinically significant acute or chronic disease that, as judged by the investigator, may increase the risk of trial drug exposure or interfere with study evaluation.
- Inadequacy for adequate colposcopic evaluation.
- Presence of any of the following conditions: 1) Pathological confirmation of adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma in the target lesion during the screening period; 2) A history of malignant tumors of the cervix, vagina, vulva, or anal region; 3) Colposcopic findings during the screening period suggesting a suspicious malignant tumor; 4) Having undergone total hysterectomy, thereby precluding assessment of cervical lesions (however, if the uterus was resected solely for benign lesions while the patient still has vulvar/vaginal/anal lesions, this does not automatically disqualify the subject); 5) Presence of any other uncurated malignant tumor in a site other than those described above within 5 years prior to enrollment (excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc.).
- Screening: Use of immunosuppressants continuously (for more than 7 days) within the 30 days prior to screening, including but not limited to: glucocorticoids (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.
- Screening: Receipt of any medication known to have anti-HPV activity (including injectable HPV prophylactic vaccines) within the 30 days prior to screening.
- History of severe allergic reactions (requiring hospitalization), severe reactions to any medication or vaccine injection, or any known or suspected allergy to any component of the study drug or formulation.
- Presence of uncontrolled systemic chronic diseases.
- Laboratory tests during the screening period meeting any of the following criteria: 1) Hemoglobin <90 g/L; 2) Neutrophil count <1.0 × 10⁹/L; 3) Platelet count <80 × 10⁹/L; 4) AST or ALT> 1.5 × ULN; 5) Creatinine clearance <60 mL/min (using the Cockcroft-Gault formula); 6) International Normalized Ratio (INR)> 1.5 × ULN; 7) HIV antibody positive; 8) HCV antibody positive (and HCV RNA positive); 9) HBsAg positive (and HBV DNA positive); 10) Active syphilis (RPR/TPPA positive and requiring treatment).
- Any history of alcohol or drug abuse that the Investigator deems likely to affect subject safety or study adherence.
- Subjects that the Investigator deems unwilling or unable to adhere to the requirements of the study protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:AVL-1100
|
Dosage and administration for the nucleic acid-based therapeutic injection for HPV infection: A total of 3 injections are to be administered, with an interval of three weeks between each dose. The product is to be administered via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the subject must remain under observation for 60 minutes, during which time a safety assessment will be conducted. Provided no serious adverse events occur, the subject may proceed with the scheduled follow-up visits. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and tolerability
時間枠:Up to Day 300
|
Dose-limiting toxicities (DLTs), as well as the incidence and severity of adverse events, etc. |
Up to Day 300
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Effectiveness
時間枠:Up to Day 300
|
The rate of HPV16/18 viral reversion to negativity at the final visit. |
Up to Day 300
|
|
Effectiveness
時間枠:Up to Day 300
|
The degree of lesion regression assessed by histopathological evaluation at the final visit. |
Up to Day 300
|
|
Immunogenic
時間枠:Up to Day 300
|
Cell-mediated antigen-specific immune response against HPV16/18. |
Up to Day 300
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- AVL-1100-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。